Analgesics use and withdrawal in people with dementia:a register-based Danish study and a systematic review by Sørensen, Anne Mette Skov et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Analgesics use and withdrawal in people with dementia
a register-based Danish study and a systematic review
Sørensen, Anne Mette Skov; Tarp, Simon; Johannsen, Peter; Lolk, Annette; Bandak,
Elisabeth; Pedersen, Hanne; Saxtrup, Niels; Kallehauge, Hanne; Solem, Espen Jimenez;
Christensen, Mikkel Bring
Published in:
Danish Medical Journal
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Sørensen, A. M. S., Tarp, S., Johannsen, P., Lolk, A., Bandak, E., Pedersen, H., ... Christensen, M. B. (2019).
Analgesics use and withdrawal in people with dementia: a register-based Danish study and a systematic review.
Danish Medical Journal, 66(12), [A5578].
Download date: 27. maj. 2020
Dan Med J 66/12 / December 2019 1
DANISH MEDICAL JOURNAL
SYSTEMATIC REVIEW
1) Department of 
Clinical Pharmacology, 
Bispebjerg and 
Frederiksberg Hospital
2) Indsatser for Rationel 
Farmakoterapi, The 
Danish Health Authority
3) The Parker Institute, 
Bispebjerg and 
Frederiksberg Hospital
4) Danish Dementia 
Research Center, 
Rigshospitalet
5) The Dementia Clinic, 
Odense University 
Hospital
6) Department of 
Internal Medicine, 
Geriatric Section, 
Glostrup, Amager and 
Hvidovre Hospital
7) General practice, 
Lægerne i Græsted
8) Elderly Psychiatric 
Team, Region 
Nordjylland
9) Department of 
Clinical Medicine, 
University of 
 Copenhagen
10) Clinical Metabolic 
Physiology, Steno 
Diabetes Center 
Copenhagen, Gentofte 
Hospital, Denmark
Dan Med J 
2019;66(12):A5578
ABSTRACT
INTRODUCTION: Pain assessment in people with dementia 
is difficult, and withdrawal of analgesics may allow for 
assessment of treatment efficacy whilst decreasing pill 
burden, adverse events and interactions. We aimed to 
describe the use of analgesics among elderly in Denmark 
and to compile the evidence for withdrawal of analgesics 
among people with dementia.
METHODS: With respect to analgesics use, we employed 
data from national registries on the analgesic prescription 
use (opioids, nonsteroidal anti-inflammatory drugs (NSAIDs) 
and acetaminophen) in 2017 among elderly people with and 
without dementia. Trial evidence was produced by 
performing a systematic search in MEDLINE, Embase and 
Cinahl for trials evaluating withdrawal of analgesics in 
people with dementia.
RESULTS: Opioids were prescribed more frequently (p = 
0.026) and NSAIDs less frequently (p = 0.026) to people with 
dementia. With respect to trial evidence, we identified two 
studies: An observational cross-over study (n = 3) reporting 
acetaminophen withdrawal leading to increases in pain 
frequency and duration, and a cluster-randomised clinical 
trial (n = 352) reporting changes in mobilization-
observation-behaviour-intensity-dementia-2 (MOBID-2) pain 
score during a four-week withdrawal period 
(acetaminophen, opioids and/or pregabaline) from a mean ± 
standard deviation of 2.3 ± 2.1 to 2.9 ± 2.6 compared with 
3.5 ± 2.6 to 3.5 ± 2.5 in the control group.
CONCLUSIONS: In Denmark, use of opioids is higher in 
elderly with dementia compared to elderly without dementia. 
The evidence suggests that withdrawal of analgesics may 
aggravate pain but increases in pain scores may be of little 
clinical relevance in most people. Clinical trials investigating 
analgesics withdrawal are warranted. 
Analgesics use and withdrawal in people  
with dementia – a register-based Danish study 
and a systematic review
Anne Mette Skov Sørensen1, Simon Tarp2, 3, Peter Johannsen4, Annette Lolk5, Elisabeth Bandak3, Hanne Pedersen6, Niels Saxtrup7, Hanne Kallehauge8, 
Espen Jimenez Solem1, 9 & Mikkel Bring Christensen1, 10 
The Danish Ministry of Health published a nationwide 
dementia plan in January 2017 [1]. Among the initia­
tives were the publication of three national clinical 
guidelines. The author group all contributed to the 
guideline concerning dementia and medicine [2]. The 
present study is based on two PICO (population (P), 
 intervention (I), comparison (C) and outcomes (O)) 
questions addressed in the guideline. These questions 
 relate to the difficulties of treating pain in people with 
dementia.
Dementia is a syndrome characterised by deterior­
ation of memory and other cognitive functions, the 
ability to perform everyday activities and changes in 
overall behaviour. Dementia is usually progressive and 
occurs primarily in the elderly with a prevalence 
around 5­7% [3]. Ageing is often accompanied by pain­
related comorbidities such as musculoskeletal disor­
ders and cancer [4­6]. Due to the increasing life expect­
ancy and the large birth cohorts after World War II, the 
number of people with dementia and painful comorbid­
ities is expected to rise [4, 7]. 
Recent evidence has shown mixed findings on the 
use of analgesics among people with dementia [8­14]. 
A Danish register­based study found that among com­
munity­dwelling people, 28% of people with dementia 
and 17% of people without dementia received an opi­
oid. The use of opioids was generally higher among 
nursing home residents, but slightly fewer nursing 
home residents with dementia (38%) were treated with 
an opioid compared with nursing home residents with­
out dementia (43%) [8]. A Finnish study found a lower 
use of opioids among people with dementia than 
among those without dementia with an annual preva­
lence of opioid use of 3.56% and 4.62%, respectively 
(adjusted odds ratio 0.77, 95% confidence interval: 
0.71­0.84) [12]. An Australian study among nursing 
KEY POINTS
 ▶ Use of opioids and acetaminophen is higher in elderly 
people with dementia than in elderly without dementia 
in Denmark.
 ▶ Evidence regarding deprescribing of analgesics 
among people with dementia is very limited but sug-
gests that deprescribing of analgesics may precipitate 
behavioural symptoms and aggravation in pain in 
some but is an option for treatment evaluation. 
 ▶ In many elderly people with dementia, analgesics may 
be withdrawn without clinically significant worsening 
in pain.
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home residents showed no significant differences in 
 analgesic drug use. Additionally, no significant differ­
ences in opioid use among people with or without de­
mentia was found, 25% and 31%, respectively. 
However a significantly lower prevalence of oxycodone 
use among people with dementia was observed [14]. 
Pain is a fluctuating condition, and combined with 
the limitations in pain assessment among people with 
dementia, a once initiated treatment may continue for 
a long time without being questioned by a healthcare 
provider. However, if feasible, withdrawal of analgesics 
may allow for evaluation of efficacy and limit the risks 
associated with polypharmacy such as drug interac­
tions and adverse events. It has previously been de­
scribed that withdrawal of antidepressants and anti­
psychotics is feasible in people with dementia [15, 16], 
but no systematic review has examined withdrawal of 
analgesics. Therefore, the aim of the study was a) to 
describe the prescription of nonsteroidal anti­inflam­
matory drugs (NSAIDs), opioids and acetaminophen 
among elderly people with and without dementia in 
Denmark and b) to identify clinical trials investigating 
the safety and efficacy of withdrawal of analgesics 
among people with dementia. 
METHODS
Data for the study were gathered from two Danish 
 registries and a systematic literature search. The sys­
tematic review was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta­analysis (PRISMA) guideline [17]. 
Data sources for epidemiological data
Epidemiological data were gathered linking diagnostic 
information with prescription redemptions from two 
Danish national registries; The Danish Register for 
 Selected Chronic Diseases and Major Psychiatric Dis­
orders and The Danish National Drug Prescription Reg­
ister, using the unique civil registration number given 
to all Danish citizens at birth [18]. The population in­
cluded all people with dementia on January 1 2017. 
People with dementia were defined as individuals who 
had a relevant diagnosis using the WHO International 
Classification of Diseases (ICD)­10 codes (F00, F01, 
F02 and F03) or who had redeemed at least two pre­
scriptions of an ATC N06D drug. We excluded people 
with an unspecific dementia diagnosis (F03.9) and no 
redemption of an N06D drug and with no hospital con­
tact registered during the past ten years. 
Analgesics were identified in the prescription reg­
ister using the Anatomical Therapeutic Chemical (ATC) 
classification. Included analgesics were NSAIDs 
(M01A), opioids (N02A) and paracetamol (N02BE). 
Data on analgesic use were gathered from January 1 
2017 to December 31 2017. Users of analgesics were 
defined as people redeeming at least one prescription 
of that analgesic.
We stratified analgesic use according to age groups 
(65­69, 70­74, 75­79, 80­84, 85­89 and 90+ years). 
Statistical analyses of epidemiological data
Standard descriptive statistics were applied to examine 
the association between analgesic use and dementia. 
The statistical analyses, unpaired t­tests and two­way 
ANOVA, were performed using Graphpad Prism, version 
7 (GraphPad Software, La Jolla, CA, USA). A two­sided 
p­value < 0.05 was considered statistically significant. 
FIGURE 1 / Analgesic use among elderly with and without 
dementia. Patients with a prescription of opioid (A), 
 acetaminophen (B) or NSAID (C) as percentage of population. 
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Systematic literature search
The aim of the systematic literature search was to com­
pile and review literature addressing withdrawal of 
analgesics in people with dementia. PICO­based ques­
tions concerning withdrawal of opioids and acetamin­
ophen were determined prospectively (as part of a clin­
ical guideline issued by the Danish Health Authority) 
[2] before the search was performed [19]. The syste­
matic literature search was performed by a search spe­
cialist in accordance with the method description from 
the Danish Health Authority [19] and was divided into 
three steps; first we searched for guidelines, subse­
quently for systematic reviews and finally for random­
ised controlled trials. Reference lists of included ar­
ticles were searched for additional studies. See for the 
detailed search strategies. The search strategy for 
guidelines was individualised for each database and is 
available upon request. The systematic search of 
 MEDLINE, Embase and Cinahl was conducted from 
J anuary to March 2018. The search strategy included 
terms synonymous with “opioid”, “acetaminophen” and 
“dementia”.
In all three steps, one author (AMSS) first screened 
the title and abstract, and in the next step three authors 
(AMSS, MBC and HP) screened the full­text papers. 
Disagreement concerning study eligibility was resolved 
by consulting another review author (EB). Data extrac­
tion was performed in duplicate by AMSS and EB.
Study selection
Studies were included if they fulfilled the following 
crit eria: 1) Included people with dementia. All diagno­
ses of dementia were eligible. 2) The intervention in­
cluded withdrawal of analgesics. Both abrupt and step­
wise tapering was acceptable. Studies that were 
primarily treatment trials, but included a withdrawal 
period were also eligible for inclusion. 3) Only studies 
with publications in English, German or Scandinavian 
languages were included. There were no limits regard­
ing publication year.
We excluded qualitative studies and studies with 
 tapering, but not withdrawal of analgesics.
RESULTS
Analgesic use among people with dementia  
in Denmark in 2017
The use of opioids, acetaminophen and NSAID for 
people with and without dementia is presented in 
 Figure 1. For people ≥ 65 years, the proportion pre­
scribed an opioid was higher among those with demen­
tia (p = 0.026). Stratified on age (65­69, 70­74, 75­79, 
80­84, 85­89 and > 90 years), the association was stat­
istically significant in all age groups. For people ≥ 65 
years, the proportion prescribed acetaminophen was 
higher among those with dementia, though not statis­
tic ally significant (p = 0.073). The association was also 
not statistically significant in any of the aforemen­
tioned age groups. A different pattern was apparent for 
NSAID. For people ≥ 65 years, the proportion pre­
scribed NSAID was higher among elderly people with­
out dementia (p = 0.026). Stratified on age, the associ­
ation was significant in three age groups (70­74, 75­79 
and 80­84 years).
Identification of studies addressing withdrawal  
of analgesics in people with dementia
The initial search for guidelines yielded no relevant re­
sults. The search for randomised controlled trials and 
systematic reviews yielded two studies representing 
five published papers meeting the inclusion criteria 
( Figure 2). We did not identify studies directly investi­
gating withdrawal of analgesics in people with demen­
tia, but the two included trials contained withdrawal 
periods. Results are presented narratively due to the 
heterogeneity of the limited number of studies.
Results of studies addressing withdrawal  
of  analgesics in people with dementia
Characteristics and results of the included studies are 
presented in Table 1.
Study 1 investigated the efficacy of acetaminophen 
on pain behaviours and included two baseline (no­
treatment) phases [20]. The study lasted 24 days and 
included three people with a diagnosis of dementia and 
FIGURE 2 / Flow chart for systematic reviews and randomised controlled trials.
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a history of osteoarthritis (mean age: 85 years). During 
treatment phases, the participants received acetamin­
ophen 1.3 g (two 650 mg tablets, extended release) 
every eight hours. The effect was assessed daily with an 
activity­based protocol consisting of normal activities 
of daily living, e.g. standing, sitting, walking. The activ­
ities were videotaped and coded by two raters. Data 
were reported for each participant individually. During 
treatment, the frequency and duration of pain behav­
iours decreased for all three participants. Furthermore, 
the frequency and duration of pain behaviours in­
creased for all three participants when treatment was 
withdrawn. Whether the changes were statistically sig­
nificant was not described.
Study 2 investigated a stepwise analgesic treatment 
approach among 352 nursing home residents with de­
mentia and neuropsychiatric symptoms from 18 differ­
ent nursing homes in Norway (mean age: control group 
87 years and intervention group 85 years) [21­24].  
The study was a cluster­randomised clinical trial lasting 
12 weeks with the last four weeks being a withdrawal 
 period. Participants randomised to active treatment 
 received a stepwise treatment approach with initial 
acetaminophen followed by morphine, buprenorphine 
and/or pregabaline based on clinical evaluation of indi­
vidual needs. Of 175 participants in the intervention 
group, 69% received acetaminophen, 2% received mor­
phine, 22% received buprenorphine and 7% received 
pregabaline. Outcomes were measured at baseline and 
at weeks two, four, eight and 12. At baseline, 59% of 
the intervention group and 55% of the control group 
had a mobilization­observation­behaviour­intensity­ 
dementia­2 (MOBID­2) score ≥ 3, which is accepted as 
clinically relevant. The MOBID­2 scores increased from 
a mean (± standard deviation (SD)) of 2.3 (± 2.1) in 
week 8 to 2.9 (± 2.6) in week 12 in the intervention 
group (indicating an increase in pain). The change was 
reported to be statistically significant (p = 0.022). The 
Cohen­Mansfield Agitation Inventory score increased 
from a mean (± SD) of 46.9 (± 18.7) in week eight to 
50.3 (± 20.3) in week 12 in the intervention group 
( indicating an increase in agitation).
Quality of evidence
The two identified studies containing an analgesics 
 withdrawal period among people with dementia were 
conducted in two different countries (United States 
and Norway) and were heterogeneous regarding study 
design, population, intervention and outcomes. 
The results from the study by Elliott & Horgas 
should be interpreted with caution due to a high risk of 
bias [20] which included no blinding of participants, 
caregivers or the primary rater, who coded all video­
taped protocols. In addition, the generalisability of the 
results is further limited by the very limited number of 
participants who all had a relevant pain diagnosis, were 
home dwelling and able to perform a daily activity 
 protocol indicating a high performance status. The trial 
by Husebo et al had a low risk of bias. It was a ran­
domised trial, which had measures in place to blind 
 research assistants and caregivers, though the study 
was not placebo­controlled [21­24]. 
DISCUSSION 
This review summarises the very limited published 
 evidence describing the consequences of discontinuing 
analgesics in people with dementia and underlines 
that, in some people, withdrawal may precipitate 
 behavioural symptoms and aggravation of pain. 
The register data show a high use of opioids and 
acetaminophen among elderly with dementia in 
Denmark. Interestingly, the use of NSAIDs was higher 
among elderly without dementia than among age­
matched people with dementia. In several countries, 
opioid prescriptions have increased during the past 
decades (though it has decreased in the United States 
TABLE 1 / Clinical studies investigating withdrawal of analgesics in people with dementia.
Reference Population Design Intervention Comparison Outcome measures Findings
Elliot & Horgas,  
2009, USA [20]
3 people living at home 
with a dementia diagno-
sis and a history of 
osteoarthritis 
ABAB-single case- 
design over 24 days
Acetaminophen 1.3 g every  
8 h during treatment phases
Activity protocol during all 
phases 
Activity 
 protocol
Pain behaviour: fre-
quency and duration, co-
ded using the Noldus the 
Observer behaviour ana-
lysis software
Pain treatment led to 
 decreases in the frequency 
and duration of pain
Withdrawal led to the opposite
Husebo et al,  
2011-2014, Norway  
[21, 22, 24, 27]
352 NH residents with 
moderate-severe 
 dementia and agitation
Cluster-randomised 
trial over 8 wks with 
additional follow-up  
4 wks after the end of 
treatment
Stepwise treatment approach 
with acetaminophen, 
morphine, buprenorphine and/
or pregabaline
Usual 
 treatment
CMAI, NPI-NH, MMSE, 
MOBID-2, ADL
CMAI and MOBID-2 scores 
 increased from wk 8 to wk 12 
in the intervention group
The change was reported to be 
statistically significant 
 regarding the latter
ABAB design = phases A and B are alternated; ADL = activities of daily living; CMAI = Cohen-Mansfield Agitation Inventory; MMSE = Mini-Mental State Examination;  
MOBID-2 = Mobilization-Observation-Behaviour-Intensity-Dementia; NH = nursing home; NPI-NH: = Neuropsychiatric Inventory – NH version.
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during the past years) and this might be part of the ex­
planation for the observed high use of opioids [25, 26]. 
However, this cannot explain the discrepancy between 
elderly with and without dementia which, in turn, con­
trasts with some of the previous studies on analgesic 
use. The important point as to whether the substantial, 
and higher than average, use of analgesics among 
 elderly with dementia reflects appropriate drug use 
 remains uncertain and needs to be clarified. 
In the study by Husebo et al, withdrawal of treat­
ment resulted in a deterioration of mean values of both 
agitation and pain scores, which was statistically signif­
icant in the latter case. A previous study found that 
score changes in the MOBID­2 scale ≥ 3 were clinically 
relevant [27]. Therefore, the observed changes in the 
MOBID­2 score of less than one, albeit statistically 
 significant, are likely not clinically relevant in most 
people. It is noteworthy that only 59% of the interven­
tion group and 55% of the control group had clinically 
relevant pain scores (defined as pain scores ≥ 3 on the 
MOBID­2 scale) at baseline [21­24]. As results were 
presented for the entire intervention group, it remains 
unknown whether the effect of the intervention and 
withdrawal differs for the subgroups with and without 
clinically relevant pain scores at baseline. This seems 
likely though, taking into consideration the limited 
change in MOBID­2 scores and the rather large associ­
ated standard deviations (MOBID­2 scores increased 
from a mean (± SD) of 2.3 (± 2.1) in week eight to 2.9 
(± 2.6) in week 12 in the intervention group).A lower 
effect on pain measures in people without relevant pain 
would be a reasonable assumption, and these are actu­
ally the ones in whom withdrawal may be most rele­
vant.
The complex issue of treating pain in people with 
dementia has been reviewed several times. In a system­
atic review, Pieper et al included six studies that as­
sessed pain interventions targeting behaviour in de­
mentia [28]. Overall, the studies indicated that pain 
medication is effective in reducing pain and behav­
ioural symptoms. In another systematic review, Husebo 
et al included eight studies that investigated the effect 
of analgesics on pain or behavioural symptoms [29]. 
The studies included treatment with acetaminophen, 
morphine, lidocaine and vitamin D. The authors em­
phasised the lack of evidence regarding pain manage­
ment in people with dementia. 
Strengths and limitations
The present study has several limitations. In the reg­
ister­based part of the study, people with dementia 
were defined as individuals who redeemed at least one 
prescription of an ATC N06D­drug or who had a rele­
vant diagnosis using the ICD­10 codes. It is possible 
that we underestimated the actual number of people 
with dementia by using this definition. Furthermore, 
although a physician prescribed an analgesic and the 
prescription was redeemed, we have no information to 
establish if the drug was taken. 
To our knowledge, this systematic review is the first 
concerning withdrawal of analgesics among people 
with dementia. We performed thorough searches for 
publications in all major medical databases. Neverthe­
less, the very limited number of identified trials, includ­
ing one with a very small sample size, and the low 
 quality of evidence severely limits the conclusions that 
may be drawn about withdrawal of analgesics in people 
with dementia. As the use of opioids has been increas­
ing worldwide, we believe that our findings are appli­
cable outside Denmark. This review highlights the need 
for further research to clarify the consequences of dis­
continuing analgesics in people with dementia. 
CONCLUSIONS
Use of opioids in Denmark is higher in people with de­
mentia than in an age­matched population without de­
mentia. It remains unclear whether the substantial use 
of opioids among people with dementia in Denmark 
 reflects appropriate pharmacotherapy. The evidence 
regarding withdrawal of analgesics among people with 
dementia is very limited but suggests that although 
withdrawal may precipitate behavioural symptoms and 
worsening in pain in some, it is an option for treatment 
evaluation and deprescribing in many.
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